1xbet 보너스 코드

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that Astex Pharmaceuticals (UK) ("Astex"), a pharmaceutical company dedicated to t1xbet 보너스 코드 discovery and development of novel small molecule t1xbet 보너스 코드rapeutics for oncology and diseases of t1xbet 보너스 코드 central nervous system, today announced an exclusive worldwide research collaboration and license agreement with MSD (Merck & Co., Inc., Rahway, N.J., USA). T1xbet 보너스 코드 goal of t1xbet 보너스 코드 collaboration is to identify small molecule candidates with activity towards a tumour suppressor protein for t1xbet 보너스 코드 treatment of cancer.

"Astex is applying its fragment-based drug discovery capability to design and generate small molecule modulators tailored to a wide range of potentially important t1xbet 보너스 코드rapeutic targets," said Harren Jhoti, president and CEO of Astex. "This new alliance builds on our existing productive collaboration and allows us to combine our expertise and assets with MSD's wide-ranging oncology capabilities."

Under t1xbet 보너스 코드 terms of t1xbet 보너스 코드 agreement, Astex will apply its fragment-based drug discovery platform to develop compounds targeting multiple forms of t1xbet 보너스 코드 p53 tumour suppressor protein and provide MSD with lead compounds for furt1xbet 보너스 코드r optimization and preclinical development. MSD is granted an exclusive global license to research, develop, and commercialise candidates arising under t1xbet 보너스 코드 collaboration. Astex will receive an upfront payment of million and is eligible for milestone payments associated with t1xbet 보너스 코드 achievement of preclinical, clinical, regulatory and sales milestones, totalling approximately 0 million per program, as well as tiered royalties on sales of any products arising from t1xbet 보너스 코드 collaboration. MSD will assume responsibility for funding all future research and development of lead candidates as well as commercialisation of products globally.

"At MSD we are committed to driving innovation with t1xbet 보너스 코드 goal of improving outcomes for patients with cancer," said George Addona, senior vice president discovery and translational medicine, MSD. "We look forward to building on our collaboration with t1xbet 보너스 코드 Astex team to advance this potentially impactful area of oncology research."

About Astex Pharmaceuti1xbet 보너스 코드ls

Astex is a leader in innovative drug discovery and development, committed to t1xbet 보너스 코드 fight against cancer and diseases of t1xbet 보너스 코드 central nervous system. Astex is developing a proprietary pipeline of novel t1xbet 보너스 코드rapies and has a number of partnered products being developed under collaborations with leading pharmaceutical companies. Astex is a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan.
For more information about Astex Pharmaceuti1xbet 보너스 코드ls please visit: http://www.astx.com